Compare VIRC & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | INO |
|---|---|---|
| Founded | 1950 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 100.4M |
| IPO Year | 1995 | 1999 |
| Metric | VIRC | INO |
|---|---|---|
| Price | $6.11 | $0.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.30 | $6.75 |
| AVG Volume (30 Days) | 33.6K | ★ 3.4M |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $199,652,000.00 | $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | $19.77 | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $5.16 | $0.56 |
| 52 Week High | $9.07 | $2.86 |
| Indicator | VIRC | INO |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 23.53 |
| Support Level | $6.01 | N/A |
| Resistance Level | $6.37 | $1.24 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 88.61 | 21.85 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.